Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Meningococcal B vaccine and meningococcal carriage in adolescents in Australia

Among Australian adolescents, the 4CMenB vaccine had no discernible effect on the carriage of disease-causing meningococci, including group B

Research

Impact of covid-19 restrictions on western Australian children’s physical activity and screen time

Physical activity is essential for children’s healthy development, yet COVID-19 physical distancing restrictions such as school closures and staying at home, playground closures, and the cancelling of organised community sport have dramatically altered children’s opportunities to be physically active. This study describes changes in levels of physical activity and screen time from February 2020 (i.e., before COVID-19 restrictions were introduced in Western Australia) to May 2020 (i.e., when COVID-19 restrictions were in place). Parents of children aged 5 to 9 years from Western Australia were eligible to participate and recruited through convenience sampling.

Research

Zika Virus Changes Methylation of Genes Involved in Immune Response and Neural Development in Brazilian Babies Born With Congenital Microcephaly

The recent increase in babies born with brain and eye malformations in Brazil is associated with Zika virus (ZIKV) infection in utero. ZIKV alters host DNA methylation in vitro. Using genome-wide DNA methylation profiling we compared 18 babies born with congenital ZIKV microcephaly with 20 controls. We found ZIKV-associated alteration of host methylation patterns, notably at RABGAP1L which is important in brain development, at viral host immunity genes MX1 and ISG15, and in an epigenetic module containing the causal microcephaly gene MCPH1. Our data support the hypothesis that clinical signs of congenital ZIKV are associated with changes in DNA methylation.

Research

A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C

Safe, highly curative, short course, direct acting antiviral (DAA) therapies are now available to treat chronic hepatitis C. DAA therapy is freely available to all adults chronically infected with the hepatitis C virus (HCV) in Australia. If left untreated, hepatitis C may lead to progressive hepatic fibrosis, cirrhosis and hepatocellular carcinoma.

Research

Detection of the rapid emergency of the H274 mutation associated with oseltamivir-resistance

In 2009 a new swine-origin influenza virus A/H1N1 (A/H1N1 09) emerged, causing the century's first pandemic.

Research

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years

We report data from the interim analysis of the ongoing VIVIANE study, the aim of which is to assess the efficacy, safety, and immunogenicity of the HPV...

News & Events

New ear health study music to the ears of Aboriginal children

Wait times for Aboriginal children suffering ear infections could be reduced to less than four weeks thanks to a new The Kids Research Institute Australia research project

News & Events

The Kids Research Institute Australia researcher recognised for saving children in PNG

Clinical Associate Professor Deborah Lehmann has been recognised for her dedication to reducing the burden of infectious diseases in Papua New Guinea (PNG) with an award supporting research in the Western Pacific named in her honour.

News & Events

Researchers share their expertise with the community in Cockburn

Researchers from the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia have shared their expertise with the community in Cockburn, covering topics ranging from respiratory disease in babies to recurring ear infections in kids.

Research

Comorbidities and confusion: addressing COVID-19 vaccine access and information challenges

Early in the coronavirus disease 2019 (COVID-19) pandemic, evidence emerged that individuals with chronic and immunocompromising conditions faced increased risk of severe infection, including death. The Australian Government and public health authorities prioritised these citizens' access to vaccines, including them in phase 1b of the rollout from 22 March 2021.